Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment
Authors:
- Björn WettermarkBWBjörn Wettermark
- Brian GodmanBGBrian Godman
- Martin NeoviusMNMartin Neovius
- Niklas HedbergNHNiklas Hedberg
- Tor-Olov MellgrenTMTor-Olov Mellgren
- Thomas KahanTKThomas Kahan
- 31 March 2010
- journal article
- Published by Elsevier in Health Policy
- Vol. 94 (3) , 221-229
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Trends in Hypertension Prevalence, Awareness, Treatment, and Control Rates in United States Adults Between 1988–1994 and 1999–2004Hypertension, 2008
- Utilisation of angiotensin receptor blockers in Sweden: combining survey and register data to study adherence to prescribing guidelinesEuropean Journal of Clinical Pharmacology, 2008
- Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers for Treating Essential HypertensionAnnals of Internal Medicine, 2008
- Recent National and Regional Drug Reforms in SwedenPharmacoEconomics, 2008
- Pharmaceutical Pricing and Reimbursement Policies in SwedenSSRN Electronic Journal, 2007
- Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysisThe Lancet, 2005
- Blood Pressure Reduction and Cardiovascular Prevention: An Update Including the 2003-2004 Secondary Prevention TrialsHypertension Research, 2005
- Does comorbidity explain trends in prescribing of newer antihypertensive agents?Journal Of Hypertension, 2004
- Treatment for newly diagnosed hypertension: patterns of prescribing and antihypertensive effectiveness in the UKJournal of the Royal Society of Medicine, 2003
- Hypertension Prevalence and Blood Pressure Levels in 6 European Countries, Canada, and the United StatesJAMA, 2003